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BACKGROUND: Current asthma guidelines advocate
early therapy with inhaled corticosteroids to reduce bron-
chial inflammation. The aim of the present study was to
examine the association between compliance with preven-
tive therapy (inhaled corticosteroids, sodium cromogly-
cate, and nedocromil) and hospitalization for asthma.
METHODS: From the Tayside MEMO record-linkage
database we identified a cohort of subjects receiving pre-
scriptions for inhaled corticosteroids. Subjects aged 12–45
years, with at least 3 months’ exposure during the period
August 1992 to December 1994, were included in the
study. Compliance was estimated by calculating the max-
imum number of days for which a subject could have
taken an inhaled corticosteroid. In the 3-month exposure
window, subjects with 90 days therapy were designated
as “compliant,” those with 1–89 days were defined to be
“partially compliant,” and those with zero days were “non-
compliant.”
RESULTS: Of the subjects, 4535 provided calculable
compliance, with a total of 88 occurrences of hospitaliza-
tion for asthma. The proportion of subjects with hospital-
ization was 9% for compliant subjects, 3% for partially
compliant subjects, and 1% for noncompliant subjects.
The odd-ratios (ORs) for partial compliance versus com-
pliance were: 0.34 (95% confidence interval [CI] 0.19–
0.62) and 0.10 (95% CI 0.05–0.19) for noncompliance
versus compliance. The association between compliance
and hospitalization disappeared after adjustment for
number of doses of beta-agonists and the number of types
of medication taken for relief of asthma.
CONCLUSION: As the degree of compliance increased,
the incidence of hospitalization with asthma also in-
creased. However, this association was probably due to
worsening symptoms leading to better compliance with
all medications. The results suggest that patients with
asthma take their preventive medications more regularly
when the condition is worsening.
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OBJECTIVE: Oral ciprofloxacin is an antibiotic com-
monly used for ambulatory treatment of exacerbations of
chronic airway diseases (ECAD). However, its clinical su-
periority over other antibiotics remains to be proven.
Randomized clinical trials in which efficacy was mea-
sured with bacterial eradication and disappearance of
symptoms provided inconclusive results.
METHODS: Using the administrative databases of the
Quebec Health Insurance Plan, we assessed the effective-
ness of oral ciprofloxacin in the ambulatory treatment of
ECAD among patients aged over 65 years. Within a co-
hort of 10,820 subjects (mean age 73 years) followed
from 1989 to 1996, we performed a case-control analysis
to determine whether oral ciprofloxacin prevents hospi-
talizations for ECAD.
RESULTS: During the first 7 days of therapy, 465 cases
of hospitalization for ECAD occurred, while 175 cases
occurred after the seventh day of therapy. After adjusting
for markers of disease severity, we found that users of
oral ciprofloxacin were less likely to be hospitalized than
users of other antibiotics during the early part of therapy
(1–7 days) (rate ratio  0.6; 95% CI 0.4–1.0). However,
after 7 days of therapy we found that users of ciprofloxa-
cin were more likely to be hospitalized for ECAD (rate
ratio  1.7; 95% CI 1.1–3.3).
CONCLUSION: Ciprofloxacin was found to be associ-
ated with a reduction in hospitalizations for ECAD com-
pared with other antibiotics early in the course of ther-
apy, but with an increase in hospitalizations after 7 days
of therapy. The lack of effectiveness in the later part of
therapy is likely due, at least in part, to confounding by
indication.
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OBJECTIVE: Concepts of quality of life are gaining in-
creasing significance as measures of outcome, both in med-
icine as well as in economics. Therefore—particularly for
chronic illnesses such as asthma—instruments are nec-
essary which make the influence of the illness on the
daily life of the patients measurable from a subjective
point of view. One such questionnaire is the Fragebogen
zur Asthmaqualität (FLA), a disease-specific instrument for
measuring the quality of life of asthma patients. This ques-
